Viz.ai and Avicenna.AI Launch AI Care for Pulmonary Embolism & Aortic Disease

Viz.ai and Avicenna.AI Launch AI Care for Pulmonary Embolism & Aortic Disease

San Francisco and Paris – July 15, 2021Viz.ai, the world leader in AI-driven intelligent care coordination has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease (AD). The collaboration will pave the way for faster clinical decision making and care for patients suffering from these two life threatening conditions.

Diagnosis and care coordination of patients suffering from PE and aortic disease can be challenging. Avicenna.AI’s FDA-approved algorithms for PE and Type A and Type B aortic dissection (AD), leveraged on the Viz intelligent care coordination platform, will empower multidisciplinary care teams to easily coordinate patient care by sending notifications paired with dynamic imaging and detailed patient information to each provider’s desktop or mobile device as soon as a PE or an aortic dissection is detected. As part of Viz.ai’s commercial aortic module offering, access to imaging and workflows supporting the coordination of care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis and transection will be available in addition to the AD algorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercial PE module.

“The addition of AI powered workflows should decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening PE and aortic disease, as it has in the treatment of ischemic stroke. It will help to facilitate faster and easier treatment decisions across health systems, and this should improve outcomes for patients,” said Dr. Richard Saxon, interventional radiologist Tri-City Medical Center.

The Viz Platform is clinically proven and validated by Medicare, which reimburses hospitals directly via a New Technology Add-On Payment for Viz LVO, the time-saving ischemic stroke product. Pairing team alerts enhanced by AI with high-fidelity mobile image viewing, patient information and full-stack secure communication enables multidisciplinary teams to make faster treatment decisions for patients. The result increases access to care and improves outcomes for patients.

“We are proud to become a trusted partner of Viz.ai, who is committed to giving access to high-standard healthcare systems worldwide. Thanks to our AI-based solutions, we hope to facilitate an optimal medical response within a short time frame and improve patient care. We look forward to bringing the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond,” said Cyril Di Grandi, chief executive officer of Avicenna.AI.

PE is a potentially deadly form of venous thromboembolic disease, a common cause of cardiovascular death, and is associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery in the lung, blocking blood flow to part of the lung. Similar to PE, aortic disease is potentially deadly and can require urgent surgical intervention to prevent death.

“We’re delighted to partner with Avicenna to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz.AI platform, where any patient with life threatening diseases can benefit from AI powered triage, fast mobile communication and synchronized care coordination,” said Dr. Chris Mansi, Viz.ai CEO and co-founder. “This partnership will bring the advantages of artificial intelligence to more patients and help hospitals achieve better clinical outcomes.”

About Viz.ai, Inc.
Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s clinically validated platform leverages advanced deep learning to communicate time-sensitive information to specialists who can more quickly and easily make treatment decisions for the patient. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.

Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures, Innovation Endeavors, Susa Ventures, Scale Venture Partners and Insight Partners.

Click here and find out more about Viz.ai.

Avicenna.AI Joins Nuance AI Marketplace, Offering Cutting-Edge Solutions for Diagnostic Imaging

Avicenna.AI Joins Nuance AI Marketplace, Offering Cutting-Edge Solutions for Diagnostic Imaging

Marseille, France – 29th June, 2021Avicenna.AI today announced that their FDA-cleared applications for neurovascular emergencies, CINA-ICH & CINALVO, are available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

CINA offers radiologists an unparalleled solution for triaging patients with positive impact on high occurrence life-threatening pathologies. CINA-ICH and CINA-LVO automatically detect and prioritize acute intracranial hemorrhage and large vessel occlusion cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 9,000 connected healthcare facilities. Radiologists can discover, test, and use AI models from within their familiar Nuance PowerScribe reporting and workflow orchestration solutions to increase reporting efficiency and quality, and to help care teams improve patient outcomes and healthcare costs. A built-in feedback channel lets users share real-world results with developers for model refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing AI usage, costs, and performance.

“We are glad to partner with a global partner such as Nuance who shares our same values to put patient care at the core of their business. Together we are committed to transforming medical imaging by empowering radiologists in their daily tasks. Thanks to this partnership and our combined solutions, we aim to advance the future of healthcare,said Cyril Di Grandi, Chief Executive Officer and co-founder of Avicenna.AI.

Arterys & Avicenna.AI Join Forces on AI Stroke Detection

Arterys & Avicenna.AI Join Forces on AI Stroke Detection

San Francisco, CA & Paris, FRANCE – December 1, 2020 – Medical imaging AI specialist Avicenna.AI today announced that its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.

Arterys has fully integrated the CINA Head AI algorithms and will make them available via its FDA-cleared MICA platform to its installed base in the coming weeks. The platform’s cloud SaaS model enables CINA Head’s workflow-enhancing algorithms to be delivered instantly to any of Arterys’ existing customers.

“Given CMS’s recent NTAP reimbursement decision regarding AI-powered LVO detection, we believe that AI is finally ready to transform clinical practice, and we’re excited to make Avicenna’s AI innovations available to doctors around the world,” said John Axerio-Cilies, Arterys co-founder and CEO. “We’ve tuned the experience for seamless workflow integration—towards the ends of efficient and effective analysis of non-contrast head CTs and CTAs and accurate detection of intracranial hemorrhages and LVO strokes.”

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

“Arterys’s platform is the most agile in this new internet-based era of medical AI,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “They help companies like us go from code-to-clinic in weeks not years, giving radiologists the ability to instantly enhance their workflows with our AI – whenever they want to.”

About Arterys

Arterys is the market leader and the world’s first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. For more information on Arterys, please Arterys website.

Avicenna.AI Partners With Canon Medical on AI Stroke Detection

Avicenna.AI Partners With Canon Medical on AI Stroke Detection

Paris, FRANCE – November 10, 2020 – Medical imaging AI specialist Avicenna.AI today announced a partnership with Canon Medical Systems Corporation to deliver a fully integrated stroke detection AI solution for Canon’s Automation Platform.

With this partnership, Avicenna provides Canon with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.

Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.

Toshiki Kato, General Manager of Healthcare IT, Canon Medical Systems, said, “Our partnership with Avicenna demonstrates our commitment to providing our customers with AI solutions that help them to improve the quality of care. With its proven ability to help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care, CINA Head is exactly the kind of innovative solution that we want to offer clinicians.”

Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a medical imaging modality leader like Canon Medical Systems is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond.”

About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical, we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon.